These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 26377940)

  • 1. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
    Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
    Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
    Li JL; Sainson RC; Shi W; Leek R; Harrington LS; Preusser M; Biswas S; Turley H; Heikamp E; Hainfellner JA; Harris AL
    Cancer Res; 2007 Dec; 67(23):11244-53. PubMed ID: 18056450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.
    Hoey T; Yen WC; Axelrod F; Basi J; Donigian L; Dylla S; Fitch-Bruhns M; Lazetic S; Park IK; Sato A; Satyal S; Wang X; Clarke MF; Lewicki J; Gurney A
    Cell Stem Cell; 2009 Aug; 5(2):168-77. PubMed ID: 19664991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.
    Huang J; Hu W; Hu L; Previs RA; Dalton HJ; Yang XY; Sun Y; McGuire M; Rupaimoole R; Nagaraja AS; Kang Y; Liu T; Nick AM; Jennings NB; Coleman RL; Jaffe RB; Sood AK
    Mol Cancer Ther; 2016 Jun; 15(6):1344-52. PubMed ID: 27009216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
    Fischer M; Yen WC; Kapoun AM; Wang M; O'Young G; Lewicki J; Gurney A; Hoey T
    Cancer Res; 2011 Mar; 71(5):1520-5. PubMed ID: 21193546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delta-like 4/Notch signaling and its therapeutic implications.
    Yan M; Plowman GD
    Clin Cancer Res; 2007 Dec; 13(24):7243-6. PubMed ID: 18094402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
    Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
    Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of delta-like ligand 4 signaling inhibits both growth and angiogenesis of pancreatic cancer.
    Oishi H; Sunamura M; Egawa S; Motoi F; Unno M; Furukawa T; Habib NA; Yagita H
    Pancreas; 2010 Aug; 39(6):897-903. PubMed ID: 20182391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of CXCR4 by the Notch ligand delta-like 4 in endothelial cells.
    Williams CK; Segarra M; Sierra Mde L; Sainson RC; Tosato G; Harris AL
    Cancer Res; 2008 Mar; 68(6):1889-95. PubMed ID: 18339870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
    McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
    J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
    Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
    Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth.
    Segarra M; Williams CK; Sierra Mde L; Bernardo M; McCormick PJ; Maric D; Regino C; Choyke P; Tosato G
    Blood; 2008 Sep; 112(5):1904-11. PubMed ID: 18577711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of ephrinB2 in nonproductive angiogenesis induced by Delta-like 4 blockade.
    Yamanda S; Ebihara S; Asada M; Okazaki T; Niu K; Ebihara T; Koyanagi A; Yamaguchi N; Yagita H; Arai H
    Blood; 2009 Apr; 113(15):3631-9. PubMed ID: 19218547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrin cytoplasmic domain-associated protein-1 attenuates sprouting angiogenesis.
    Brütsch R; Liebler SS; Wüstehube J; Bartol A; Herberich SE; Adam MG; Telzerow A; Augustin HG; Fischer A
    Circ Res; 2010 Sep; 107(5):592-601. PubMed ID: 20616313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
    J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis.
    Djokovic D; Trindade A; Gigante J; Badenes M; Silva L; Liu R; Li X; Gong M; Krasnoperov V; Gill PS; Duarte A
    BMC Cancer; 2010 Nov; 10():641. PubMed ID: 21092311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The vascular endothelial growth factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?].
    Grépin R; Pagès G
    J Soc Biol; 2009; 203(2):181-92. PubMed ID: 19527632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth.
    Thurston G; Noguera-Troise I; Yancopoulos GD
    Nat Rev Cancer; 2007 May; 7(5):327-31. PubMed ID: 17457300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
    Chiorean EG; LoRusso P; Strother RM; Diamond JR; Younger A; Messersmith WA; Adriaens L; Liu L; Kao RJ; DiCioccio AT; Kostic A; Leek R; Harris A; Jimeno A
    Clin Cancer Res; 2015 Jun; 21(12):2695-703. PubMed ID: 25724527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notch signaling regulates tumor angiogenesis by diverse mechanisms.
    Dufraine J; Funahashi Y; Kitajewski J
    Oncogene; 2008 Sep; 27(38):5132-7. PubMed ID: 18758482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.